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Background
Inadequate consideration of applicability is the most fre-
quent criticism by clinicians of randomised trials, espe-
cially regarding narrow eligibility criteria.
Aim
To calculate how many women diagnosed with breast
cancer between 1993 and 2008 in Tayside, Scotland,
would have been eligible to participate in 12 major
breast cancer trials.
Methods
Major trials were identified by reviewing phase III trials
of adjuvant treatment referenced in recent national
guidelines. This list was shortened by delegates at a
meeting of the Scottish Cancer Trials Breast Group.
Inclusion criteria for these trials were extracted from
trial protocols and applied to women in the 16-year
Tayside breast cancer dataset.
Results
33 breast cancer specialists ranked 39 trials in order of
importance with the 12 most selected included in this
study. Of 4811 women in the Tayside dataset, the num-
ber meeting eligibility criteria for the 12 trials ranged
from 822 (17%) to 3419 (71%). Reasons for exclusion
included age and comorbidity. Many women received a
treatment evaluated in a trial but would themselves not
have been eligible for the trial. For example, of 572
patients prescribed anastrazole and tamoxifen, only 281
were eligible for the trial evaluating that combination.
Work to explicitly compare treatment decisions in clini-
cal practice to trial eligibility criteria is ongoing.
Conclusions
Trialists should make their trials as widely applicable as
possible. This may not have been the case for some
major breast cancer trials, where women in the commu-
nity receiving an intervention would not themselves
have been eligible for the trial.
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